bioRxiv · 10.1101/2022.04.17.488473
Gene editing is suitable to treat GM1 Gangliosidosis: a proof-of-concept study
Abstract
Ganglioside-monosialic acid (GM1) gangliosidosis, a rare autosomal recessive disorder, is frequently caused by deleterious single nucleotide variants (SNVs) in GLB1 gene. These variants result in reduced {beta}-galactosidase ({beta}-gal) activity, leading to neurodegeneration associated with premature death. Currently, no effective therapy for GM1 gangliosidosis is available. Three ongoing clinical trials aim to deliver a functional copy of the GLB1 gene to stop disease progression. Here, we show that 41% of GLB1 pathogenic SNVs might be cured by adenine base editors (ABEs). Our results demonstrate that ABE efficiently corrects the pathogenic allele in patient-derived fibroblasts, restoring a therapeutic level of {beta}-gal activity. Unbiased off-target DNA analysis did not detect off-target editing activity in treated patients cells except a bystander edit without consequences on {beta}-gal activity. Altogether our results suggest that gene editing is an alternative strategy to cure GM1 gangliosidosis, by correcting the root cause of disease and avoiding repetitive adeno-associated virus injections.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Leclerc, D., Goujon, L., Jaillard, S., Nouyou, B., Cluzeau, L., Damaj, L., Dubourg, C., Etcheverry, A., Levade, T., Froissart, R., Dreano, S., Guillory, X., Eriksson, L. A., Launay, E., Mouriaux, F., Belaud-Rotureau, M.-A., Odent, S., Gilot, D.. 2022-04-17. Gene editing is suitable to treat GM1 Gangliosidosis: a proof-of-concept study. https://doi.org/10.1101/2022.04.17.488473
Cite the original work for its findings. Save a collection to share your selection of sources.